Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares IssuedShort-Term Debt repayments
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Incannex Healthcare (IXHL) Change in Accured Expenses (2023 - 2025)

Incannex Healthcare's Change in Accured Expenses history spans 3 years, with the latest figure at $44000.0 for Q4 2025.

  • On a quarterly basis, Change in Accured Expenses rose 101.06% to $44000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was -$3.1 million, a 287.23% decrease, with the full-year FY2025 number at $1.4 million, down 54.18% from a year prior.
  • Change in Accured Expenses hit $44000.0 in Q4 2025 for Incannex Healthcare, up from -$5.4 million in the prior quarter.
  • Over the last five years, Change in Accured Expenses for IXHL hit a ceiling of $3.3 million in Q3 2024 and a floor of -$5.4 million in Q3 2025.
  • Historically, Change in Accured Expenses has averaged -$94400.0 across 3 years, with a median of $418500.0 in 2025.
  • The widest YoY moves for Change in Accured Expenses: up 955.04% in 2024, down 567.79% in 2024.
  • Tracing IXHL's Change in Accured Expenses over 3 years: stood at $891000.0 in 2023, then plummeted by 567.79% to -$4.2 million in 2024, then soared by 101.06% to $44000.0 in 2025.
  • Business Quant data shows Change in Accured Expenses for IXHL at $44000.0 in Q4 2025, -$5.4 million in Q3 2025, and $793000.0 in Q2 2025.